ArticleFrontiers in immunology2026
IL27 expression and IL27RA-dependent cellular responses are associated with biochemical recurrence and immune-regulatory features in prostate cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Biochemical recurrence remains a clinically heterogeneous event in prostate cancer, yet the immune signals associated with relapse-prone tumors are not fully defined. This study investigated IL-27 and its receptor IL27RA as a potential immune-epithelial ligand-receptor axis linking microenvironmental inflammation, recurrence, and immune escape. Methods: Transcriptomic and clinical datasets from TCGA and GEO were analyzed to assess IL-27 expression, biochemical recurrence-free survival, clinicopathological associations, immune infiltration, pathway activity, single-cell distribution, mutation features, and druggable-target patterns. Experimental validation was performed in RWPE-1 prostate epithelial cells and PC-3 prostate cancer cells using immunofluorescence staining, recombinant IL-27 stimulation, IL27RA knockdown, CCK-8 assays, and qRT-PCR. Results: Higher IL27 expression was observed in prostate cancer and was associated with recurrence, higher Gleason score, and shorter biochemical recurrence-free survival; the association with recurrence persisted after adjustment for the clinicopathological variables included in the Cox model. Discussion: These findings identify IL27 expression as a recurrence-associated molecular feature in retrospective prostate cancer datasets and provide proof-of-concept evidence for an IL27RA-dependent response to IL-27 in PC-3 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.